http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103717590-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103717590-B |
| titleOfInvention | Quinazoline-7-ether compound and using method |
| abstract | The invention provides quinazoline-7-ether derivant, especially 4-anilino--6-crotonoyl amido-quinazoline-7-ether derivant, it is receptor protein tyrosine kinase (RTK) inhibitor. This compound can be used for the disease that relates to RTK activity or the illness for the treatment of such as excess proliferative disease (for example cancer). The preparation method of described quinazoline derivant is also provided and separately or in pharmaceutical composition as the using method of therapeutic agent. |
| priorityDate | 2011-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 159.